Steven Cohen's SLN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 119,711 shares of Silence Therapeutics plc (SLN) worth $630,877, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in SLN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 321,300 shares. Largest reduction occurred in Q1 2025, reducing 617,068 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Silence Therapeutics plc (SLN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Silence Therapeutics plc (SLN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +5,641 | Add 4.95% | 119,711 | $5.27 |
| Q4 2025 | +114,070 | New Buy | 114,070 | $6.08 |
| Q2 2025 | -16,032 | Sold Out | 0 | $0.00 |
| Q1 2025 | -617,068 | Reduce 97.47% | 16,032 | $2.82 |
| Q4 2024 | +165,300 | Add 35.34% | 633,100 | $6.88 |
| Q3 2024 | +321,300 | Add 219.32% | 467,800 | $18.18 |
| Q2 2024 | +138,300 | Add 1686.59% | 146,500 | $19.00 |
| Q1 2024 | +8,200 | New Buy | 8,200 | $21.60 |
| Q3 2023 | -86,700 | Sold Out | 0 | $0.00 |
| Q2 2023 | -262,762 | Reduce 75.19% | 86,700 | $5.50 |
| Q1 2023 | -21,100 | Reduce 5.69% | 349,462 | $6.20 |
| Q4 2022 | -180,313 | Reduce 32.73% | 370,562 | $15.25 |
| Q3 2022 | +300,875 | Add 120.35% | 550,875 | $10.03 |
| Q4 2021 | +250,000 | New Buy | 250,000 | $23.89 |
Steven Cohen's Silence Therapeutics plc Investment FAQs
Steven Cohen first purchased Silence Therapeutics plc (SLN) in Q4 2021, acquiring 250,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Silence Therapeutics plc (SLN) for 16 quarters since Q4 2021.
Steven Cohen's largest addition to Silence Therapeutics plc (SLN) was in Q3 2024, adding 467,800 shares worth $8.5 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 119,711 shares of Silence Therapeutics plc (SLN), valued at approximately $630,877.
As of the Q1 2026 filing, Silence Therapeutics plc (SLN) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Silence Therapeutics plc (SLN) was 633,100 shares, as reported at the end of Q4 2024.